EUCTR2015-004595-29-GB进行中（未招募）1 期
A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old - A Single-Dose study of Tedizolid Phosphate in Pediatrics 2<12years
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Aged 2 to <12 years at the time of consent
- •2. Receiving prophylaxis for or with a confirmed or suspected infection with Gram-positive bacteria and receiving concurrent antibiotic treatment with Gram-positive antibacterial activity
- •3. Weight >5th percentile and <95th percentile based on age
- •4. Stable condition as determined from medical history, physical examination, ECG (minimally 5-lead), vital signs, and clinical laboratory evaluations
- •5. No clinically significant ECG abnormalities in the judgment of the Investigator
- •6. Serum creatinine within 1.5 × upper limit of reference range based on age
- •7. Females must be pre-menarchal, abstinent, or practicing an effective method of birth control
- •8. Negative blood or urine beta-human chorionic gonadotropin pregnancy test (if urine test is used, it must be high sensitivity [i.e., able to detect 10 mIU/mL ß-hCG]) at the Screening Visit (post-menarchal females only)
- •9. Subjects and parents must be willing to adhere to the prohibitions and restrictions specified in this protocol
- •10. Parents or subjects’ LAR able to give informed consent and willing and able to comply with all required study procedures. Assent is also required of children capable of understanding the nature of the study (typically =7 years old)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 32
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. History of seizures, other than febrile seizures, clinically significant cardiac arrhythmia, cystic fibrosis, moderate or severe renal impairment, or any physical condition that could interfere with the interpretation of the study results, as determined by the Investigator
- •2. Use of rifampin within 14 days prior to study drug administration
- •3. Use of ranitidine, cimetidine, and antacids for subjects in Part B (oral administration) from 24 hours prior to study drug administration and throughout the study
- •4. Recent (3 month) history or current infection with viral hepatitis or other significant hepatic disease
- •5. History of drug allergy or hypersensitivity to oxazolidinones
- •6. Pregnant or breast feeding
- •7. Significant blood loss (=5% of total blood volume) within 60 days before the Screening Visit
- •8. Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject’s ability to complete and/or participate in this clinical study
- •9. Treatment with investigational medicinal product within 30 days before the infusion/dose of study drug
- •10. Need for oral administration of methotrexate, topotecan, irinotecan or rosuvastatin, during administration of oral study drug. (Administration during the follow-up period is allowed, as is administration during treatment with IV study drug.)
- •11. Use of monoamine oxidase inhibitors or serotonergic agents including tricyclic antidepressants, selective serotonin reuptake inhibitors, and serotonin 5 hydroxytryptamine receptor agonists (triptans), meperidine, or buspirone within,14 days prior to study, or planned use while on study
研究者
相似试验
进行中（未招募）
不适用
A Phase 1 Pediatric Study for PK/SafetyEUCTR2015-004595-29-Outside-EU/EEACubist Pharmaceuticals LLC32
已完成
1 期
A study to investigate the safety, tolerability and activity of IPP-201101 in healthy volunteersSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesSystemic lupus erythematosusISRCTN16878305ImmuPharma S.A16
已完成
1 期
H8H-MC-LAHXMigraineJPRN-jRCT2080224864Eli Lilly Japan K.K.21
已完成
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesRespiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12620001141932Avalyn Pharma Pty Ltd38
进行中（未招募）
不适用
A Phase I-II Pharmacokinetic/Pharmacodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients with Fabry Disease (TKT027) - TKT027Fabry DiseaseEUCTR2004-000772-14-CZTKT Inc20